Search Videos and More
Video
Post-Radical Prostatectomy (RP) Outcome for Patients with High-Risk Prostate Cancer Treated with Intense Neoadjuvant Hormone Therapy (NHT): Results of a Pooled Analysis of Contemporary Clinical Trials
Prostate cancer research: Mary-Ellen Taplin, MD details prostate cancer research findings that indicate decreased PSA relapse rate for patients with a favorable pathologic response to neoadjuvant hormone therapy prior to radical prostatectomy.
News
Immunotherapy – Targeted Drug Combination Improves Survival in Advanced Kidney Cancer
Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent have longer survival than patients treated with the standard targeted drug.
News
An Advanced Approach for Treating Localized Prostate Cancer
For many men diagnosed with early-stage, localized prostate cancer, external-beam radiation therapy offers the best chance of a cure.
News
Dana-Farber Research Supports FDA Approval for Immunotherapy Combination in Advanced Kidney Cancer
An immunotherapy agent combined with a tyrosine kinase inhibitor drug whose clinical testing as a first-line treatment in advanced kidney cancer was led by Toni K. Choueiri, MD, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, has become a standard therapy.